Background: Migraine is a prevalent neurovascular disorders with a complex pathophysiology
and therapeutic options characterized by important side effects or problems related to drug
abuse. No specific biomarkers are recognized to be univocal for this subclinical condition, yet. In this
concern microRNAs (miRNAs) have been suggested as potentially useful screening/diagnostic tool,
and research is underway to recognize the most effective candidate(s). In this concern in the present
review we Herein we highlighted miRs involvement in pain and migraine, as well as drug response
and efficacy focusing also on miRs panel results from mice model with multiple induced pain conditions,
and human patients with migraine in order to understand if there are similar miRs expression
pattern may useful into human translational studies.
Results: During human migraine attack specific miRs were found dysregulated, as well as in mouse
models with different pain conditions. Amongst all the miRs screened in mice/human suffering of pain
the miR-590-5p was found alterated. This latter miR, in mice is modulated by celecoxib, while in human
is dysregulated in the complex regional pain syndrome, condition where migraine assume a risk
factor for its development. Recently has been reported that pharmacological treatments, indirectly can
pertubate miRNA expression results. Therefore, miR-590-5p could assume an interesting double
meaning for a clinical point of view. It can be considered biomarker of general pain, including migraine
and also biomarker to evaluate the efficacy of the drug treatment. This could be of great importance
in infant-juvenile segment, where the diagnosis of migraine is very challenging. In this view,
since therapy is often started with NSAIDs herein we discuss also how the discovery of the new role
of miRNAs in determining drug efficacy open a new scenario in the pain-migraine tailored therapy
and pharmacogenomics concept.
Conclusion: miRNAs could have a pleiotropic meaning in the clinical management of migraine and
could represent biomarkers of pathology, of drug efficacy as well as drug adherence to the treatment.